Avelumab and Merkel Cell Carcinoma: Evaluating Causation
From General Health Literacy to Targeted Risk Assessment
The legacy theme of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, discussions of pharmaceutical safety typically emphasize population-level outcomes and established side effect profiles. As we pivot toward a more focused occupational exposure concern, it becomes necessary to narrow this lens to specific agent-outcome relationships that may arise in workplace settings. The transition from general health literacy to targeted risk assessment involves examining whether a particular biologic exposure—such as Avelumab, an immune checkpoint inhibitor—could be associated with the development of Merkel Cell Carcinoma. This shift requires moving beyond broad epidemiological perspectives to consider the plausibility of causation in individuals with known or suspected exposure histories. In occupational health contexts, the question is not merely whether a drug can cause a disease in clinical trials, but whether real-world exposure scenarios, including accidental or chronic contact, might elevate risk. Thus, the bridge concept here is the careful evaluation of Avelumab exposure as a potential occupational hazard, distinct from its intended therapeutic use, and the subsequent need to assess Merkel Cell Carcinoma risk among workers who may encounter this agent. This pivot sets the stage for a more granular analysis of exposure pathways and risk factors.
Clinical Presentation and Diagnosis of Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of biopsy tissue, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and chromogranin A. Clinical presentation often includes a rapidly enlarging, painless, firm, red or purple nodule on sun-exposed skin, most commonly on the head, neck, or extremities.
Avelumab Pharmacology and Reported Adverse Effects
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab is approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial, JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can include conditions such as sarcoidosis, as described in a case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may include pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions. Despite these risks, avelumab has shown promising ongoing responses in clinical trials (https://pubmed.ncbi.nlm.nih.gov/31543781/).
Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma
The query asks whether avelumab causes MCC. The evidence does not support a causal relationship in which avelumab induces the development of MCC. Instead, avelumab is used as a treatment for MCC. The mechanistic pathway involves avelumab blocking PD-L1, which is often expressed on MCC tumor cells, thereby reactivating T cell-mediated antitumor immunity. This mechanism is intended to treat existing MCC, not to cause it. Immune checkpoint inhibition, including with avelumab, has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, alternative treatments such as combined ipilimumab and nivolumab have been explored (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/).
Risk Anchors: Warnings, Causation, and Timeline
The evidence indicates that avelumab is approved specifically for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the evidence does not suggest that avelumab causes MCC. Therefore, warnings about avelumab causing MCC would not be expected. The risk of progression on avelumab therapy is a known concern, with about half of patients not responding or progressing (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who are refractory to avelumab, the evidence supports the use of alternative immune checkpoint inhibitor combinations (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients with MCC who are treated with avelumab, the primary causation consideration is whether avelumab contributed to disease progression or adverse events. The evidence shows that avelumab can cause immune-related adverse events, such as sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/), but not MCC itself. Patients who experience progression on avelumab may have underlying tumor biology that is resistant to PD-L1 inhibition. Causation analyses in such cases would focus on the natural history of MCC and the lack of durable response to avelumab, rather than avelumab causing the disease. The timeline between avelumab exposure and documented harm typically involves the onset of immune-related adverse events, which can occur weeks to months after starting therapy. For example, the case of hypercalcaemia due to sarcoidosis occurred during treatment with avelumab for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). In terms of treatment failure, progression on avelumab can occur at any time during therapy, with approximately 50% of patients not achieving a durable response (https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence does not document a timeline for avelumab causing MCC, as this is not a recognized adverse effect.
Conclusion
Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Rather, it is an approved and effective treatment for metastatic MCC. The drug is associated with immune-related adverse events, but not with the induction of MCC. Patients and clinicians should be aware of the risks of irAEs and the possibility of treatment resistance, but not of avelumab as a causative agent for MCC.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does Avelumab cause Merkel Cell Carcinoma?
No, the evidence does not support a causal relationship. Avelumab is an immune checkpoint inhibitor approved for the treatment of metastatic Merkel Cell Carcinoma (MCC). It works by blocking PD-L1 to enhance the immune response against existing MCC tumors, not by causing the disease. (https://pubmed.ncbi.nlm.nih.gov/29799096/)
What are the known adverse effects of Avelumab?
Avelumab can cause immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis, endocrinopathies, skin reactions, and sarcoidosis. For example, a case of hypercalcaemia due to reactivation of sarcoidosis has been reported (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs are due to overactivation of the immune system.
What is the timeline for harm from Avelumab exposure?
Immune-related adverse events typically occur weeks to months after starting therapy. For instance, sarcoidosis-related hypercalcaemia developed during treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). Progression of MCC on avelumab can occur at any time, with about 50% of patients not achieving durable response (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.